IDEAYA Biosciences (IDYA) Current Deferred Revenue (2018 - 2025)

IDEAYA Biosciences (IDYA) reported Current Deferred Revenue of $490000.0 for Q3 2025, down 65.95% sequentially from $1.4 million in Q3 2023.

IDEAYA Biosciences (IDYA) Current Deferred Revenue (2018 - 2025) Analysis & Trends

IDEAYA Biosciences (IDYA) has 6 years of Current Deferred Revenue data on file, last reported at $490000.0 in Q3 2025.

For the quarter ending Q3 2025, Current Deferred Revenue changed N/A year-over-year to $490000.0; the trailing twelve-month figure through Sep 2025 stood at $490000.0 (changed N/A YoY), and the FY2022 full-year result was $8.6 million, down 85.78% from the prior year.
Current Deferred Revenue fell to $490000.0 in Q3 2025, from $1.4 million in the prior quarter.
In the past five years, Current Deferred Revenue ranged from a high of $62.2 million in Q3 2021 to a low of $490000.0 in Q3 2025.
A 4-year average of $23.5 million and a median of $19.9 million in 2021 frame the typical range for Current Deferred Revenue.
Across the five-year window, Current Deferred Revenue surged 61.98% in 2022 and plunged 92.14% in 2023, its largest moves.
Tracing IDYA's Current Deferred Revenue over 4 years: stood at $60.2 million in 2021, then sank by 85.78% to $8.6 million in 2022, then sank by 83.2% to $1.4 million in 2023, then tumbled by 65.95% to $490000.0 in 2025.
Business Quant data shows IDYA's Current Deferred Revenue at $490000.0 in Q3 2025, $1.4 million in Q3 2023, and $2.8 million in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	IDEAYA Biosciences	3.21 Bn	2.54 Bn	-

Download Data